We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity, Inc. (RVTY - Free Report) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP EPS in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $684 million, up 2% year over year as well as organically. The top line surpassed the Zacks Consensus Estimate by 9.4%.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $300.9 million, indicating a decrease of 2.3% from the year-ago quarter’s level. Organically, the segment witnessed a decline of 3% year over year.
Adjusted operating income amounted to $102.9 million, down 9.8% from the prior-year quarter.
Diagnostics
This segment’s revenues totaled $383.3 million, up 5.6% on a year-over-year basis. Organically, the top line increased 5% year over year.
Adjusted operating income amounted to $101.4 million, up 24.1% from the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $237.5 million, down 5.1% year over year. Research and development expenses amounted to $49.1 million, down 7.4% from the year-ago quarter’s reported number.
Adjusted operating income improved 4.8% to $193.5 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.3%, expanding 80 basis points.
The company exited the third quarter of 2024 with cash and cash equivalents of $1.23 billion compared with $1.95 billion in the prior-quarter end.
Net cash provided by operating activities, including discontinued operations, totaled $147.9 million compared with net cash used in operating activities of $33.5 million in the year-ago quarter.
2024 Guidance
Revvity raised its earnings and updated its revenue guidance for 2024.
For 2024, the company now expects its adjusted EPS in the range of $4.83-$4.87 compared with the prior guidance of $4.70-$4.80. Revenues are now anticipated to be in the band of $2.75-$2.77 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.75 per share and $2.78 billion, respectively.
Addus HomeCare has an estimated long-term growth rate of 12.1%. ADUS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 11.5%.
Addus HomeCare shares have rallied 85.5% compared with the industry's 16.9% growth year to date.
Quest Diagnostics has an estimated long-term growth rate of 6.8%. DGX's earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics has gained 42% compared with the industry's 14.9% growth year to date.
RadNet’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.
RDNT's shares have surged 93.7% year to date compared with the industry’s 14.8% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
Revvity, Inc. (RVTY - Free Report) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP EPS in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $684 million, up 2% year over year as well as organically. The top line surpassed the Zacks Consensus Estimate by 9.4%.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $300.9 million, indicating a decrease of 2.3% from the year-ago quarter’s level. Organically, the segment witnessed a decline of 3% year over year.
Adjusted operating income amounted to $102.9 million, down 9.8% from the prior-year quarter.
Diagnostics
This segment’s revenues totaled $383.3 million, up 5.6% on a year-over-year basis. Organically, the top line increased 5% year over year.
Adjusted operating income amounted to $101.4 million, up 24.1% from the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $237.5 million, down 5.1% year over year. Research and development expenses amounted to $49.1 million, down 7.4% from the year-ago quarter’s reported number.
Adjusted operating income improved 4.8% to $193.5 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.3%, expanding 80 basis points.
Revvity Inc. Price, Consensus and EPS Surprise
Revvity Inc. price-consensus-eps-surprise-chart | Revvity Inc. Quote
Financial Update
The company exited the third quarter of 2024 with cash and cash equivalents of $1.23 billion compared with $1.95 billion in the prior-quarter end.
Net cash provided by operating activities, including discontinued operations, totaled $147.9 million compared with net cash used in operating activities of $33.5 million in the year-ago quarter.
2024 Guidance
Revvity raised its earnings and updated its revenue guidance for 2024.
For 2024, the company now expects its adjusted EPS in the range of $4.83-$4.87 compared with the prior guidance of $4.70-$4.80. Revenues are now anticipated to be in the band of $2.75-$2.77 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.75 per share and $2.78 billion, respectively.
RVTY’s Zacks Rank & Stocks to Consider
RVTY carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are Addus HomeCare (ADUS - Free Report) , Quest Diagnostics (DGX - Free Report) and RadNet (RDNT - Free Report) . While Addus HomeCare sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and RadNet carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has an estimated long-term growth rate of 12.1%. ADUS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 11.5%.
Addus HomeCare shares have rallied 85.5% compared with the industry's 16.9% growth year to date.
Quest Diagnostics has an estimated long-term growth rate of 6.8%. DGX's earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics has gained 42% compared with the industry's 14.9% growth year to date.
RadNet’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.
RDNT's shares have surged 93.7% year to date compared with the industry’s 14.8% growth.